Larimar Therapeutics (LRMR) Provides Nomlabofusp Development Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. NVDA
2. CRWV
3. SPY
4. IRON
5. EYPT
6. SLGN
7. STLD
8. CHRD
9. AMZN
10. CLF

Go back to Larimar Therapeutics (LRMR) Provides Nomlabofusp Development Update

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

March 24, 2025 7:00 AM EDT

FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval
FDA recommended measuring skin FXN concentrations to support evidence of effectiveness for accelerated approval pathway and acknowledged submitted data appear sufficient to support relationship between increased skin FXN concentrations and relevant tissues such as heart, dorsal root ganglia and skeletal muscle
Larimar is... More